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Abstract
Genomic studies of the pediatric ocular tumor retinoblastoma are paving the way for development of targeted therapies.
Robust model systems such as orthotopic xenografts are necessary for testing such therapeutics. One system involves
bioluminescence imaging of luciferase-expressing human retinoblastoma cells injected into the vitreous of newborn rat
eyes. Although used for several drug studies, the spatial and temporal development of tumors in this model has not been
documented. Here, we present a new model to allow analysis of average luciferin flux (F ) through the tumor, a more
biologically relevant parameter than peak bioluminescence as traditionally measured. Moreover, we monitored the spatial
development of xenografts in the living eye. We engineered Y79 retinoblastoma cells to express a lentivirally-delivered
enhanced green fluorescent protein-luciferase fusion protein. In intravitreal xenografts, we assayed bioluminescence and
computed F , as well as documented tumor growth by intraocular optical coherence tomography (OCT), brightfield, and
fluorescence imaging. In vivo bioluminescence, ex vivo tumor size, and ex vivo fluorescent signal were all highly correlated
in orthotopic xenografts. By OCT, xenografts were dense and highly vascularized, with well-defined edges. Small tumors
preferentially sat atop the optic nerve head; this morphology was confirmed on histological examination. In vivo, F in
xenografts showed a plateau effect as tumors became bounded by the dimensions of the eye. The combination of F
modeling and in vivo intraocular imaging allows both quantitative and high-resolution, non-invasive spatial analysis of this
retinoblastoma model. This technique will be applied to other cell lines and experimental therapeutic trials in the future.
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Introduction
The pediatric ocular tumor retinoblastoma is the prototypic
genetic cancer [1]. It is initiated in most cases by mutation of both
alleles of the RB1 gene, the first tumor suppressor gene to be
cloned, although some retinoblastomas initiate without RB1
mutation [2]. In recent years, genetic characterization of
retinoblastomas beyond loss of RB1 has provided multiple
potential targets for therapeutic intervention (reviewed in [3]),
including the oncogenes KIF14 [4], MYCN [2], E2F3 [5], DEK [5],
MDM4 [6] and SYK [7], the tumor suppressor cadherin-11 [8],
and the oncomiR cluster 17,92 [9]. However, targeted thera-
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peutics for retinoblastoma have yet to transition into the clinic.
Currently, the standard of care for this cancer involves laser
therapy or cryotherapy for small tumors, often with systemic
cytotoxic chemotherapy. Treatment of large tumors often requires
enucleation of the eye or the use of external beam radiation;
however, patients subjected to radiation therapy incur a lifetime
risk of treatment toxicity [1]. As molecular targeted therapies
become a possibility for retinoblastoma, effective animal models
are needed for testing these therapies in vivo [10].
Although genetically modified mice are popular models for
retinoblastoma, the complex derivation of such models and lack of
some shared characteristics with the human tumor [11] have led to
considerable interest in xenograft models of this cancer. In recent
years, bioluminescence imaging (BLI) has been combined with
orthotopic retinoblastoma xenografts to document tumor growth
in vivo [12,13]. One model involves intravitreal injection of
luciferase-expressing Y79 retinoblastoma cells into the eyes of
newborn (postnatal day 0, P0), wild type rats [12]. This neonate
model offers two key advantages: 1) a developmentally appropriate
host environment for these pediatric tumor cells, and 2) a naturally
immunonaı¨ve setting, circumventing the need for immunocom-
promised animals. To date, this model has been used for testing
novel treatments such as topotecan/carboplatin and topotecan/
vincristine combination therapies [12,14], viral expression of
interferon [15], a novel isoquinoline EDL-155 [16], and a histone
deacetylase inhibitor MS-275 [17].
In retinoblastoma and numerous other cancer models [18], BLI
has been used for longitudinal assessment of factors including
primary tumor development, metastasis, residual disease, and
recurrence [19–21]. Strengths of BLI for non-invasively following
tumor progression include a tightly coupled biochemistry produc-
ing chemiluminescent emission [22,23], stereospecific substrates
[24], and reactions that are governed by Michaelis-Menten
kinetics [22,25]. Nonetheless, emission from implanted tumor
cells is impacted by a multitude of factors including tissue pH [26–
28], tissue oxygenation [29], tumor blood flow [30], substrate
concentrations [31], and substrate extraction from the blood.
Moreover, image acquisition and optical physics limitations in
dense tissues at 530 nm (i.e., penetration, scatter, attenuation, etc.)
have limited the advancement of high resolution and tomographic
BLI. Interestingly, the eye as a model system sidesteps many of
these biophysical limitations, and in fact serves as a collimator for
BLI photons due to the transparent nature of the cornea and lens.
Thus this system is an apt one for further development of BLI
algorithms.
Despite the recent successes and demonstrated value of BLI in
the context of imaging neonatal rat retinoblastoma xenografts,
intraocular tumor growth in this system has not been documented
visually, and peak luminescence has been used as a surrogate for
tumor vitality in all studies to date. In the current study, we
modified this orthotopic xenograft model to allow intraocular
imaging of tumor growth and mathematical modeling of the
luciferin flux, F , to yield more physiologically relevant measure-
ments of viable tumor function over time.
Materials and Methods
Cell Culture
Y79 cells [32] were cultured in suspension in a humidified
incubator at 5% CO2, 37uC. Growth medium was Iscove’s
Modified Dulbecco’s Medium plus 10% ‘‘Gold’’ fetal bovine
serum (PAA, Linz, Austria), 100 U/mL penicillin, 100 mg/mL
streptomycin, 10 mg/mL insulin, and 55 mM b-mercaptoethanol.
The identity of the Y79 cells (a kind gift of Brenda Gallie) was
confirmed by short tandem repeat profiling and comparison to
reference data (www.atcc.org).
The lentiviral vector, pCL6LucEGwo, encodes a fusion of the
human codon usage-optimized luciferase (InvivoGen, San Diego,
CA, USA) and enhanced green fluorescent protein (EGFP;
Clontech, Mountain View, CA, USA) driven by a modified spleen
focus-forming virus (SFFV) retrovirus U3 promoter [33]. Details
on the vector and cloning will be available elsewhere (Wiek,
Hanenberg, Pollok, submitted). Replication-incompetent infec-
tious lentiviral particles in the vesicular stomatitis virus glycopro-
tein pseudotype (kindly obtained from Dirk Lindemann, Dresden,
Germany) were generated using 293T cells as previously described
[33] and high viral titers were obtained (,109 transduction units
per mL). Overnight transduction of the cells with the supernatant
resulted in significant toxicity. Therefore, a modified transduction
procedure was used. Y79 cells were transduced for 4 hours with
previously frozen supernatant at a multiplicity-of-infection of 50 in
the presence of 8 mg/ml polybrene with no significant effects on
cell viability. The transduction efficiency was determined by
measuring EGFP expression by flow cytometry (BD LSR Cell
Analyzer, BD Biosciences, San Jose, CA, USA). Approximately
99% of the Y79 cells were EGFP+.
Cell-based Assays
For proliferation assays, Y79-EGFP-luc cells (2,500 cells) were
seeded in 96-well black plates and alamarBlue added after the
indicated times. Four hours after alamarBlue addition, fluores-
cence (lex = 560 nm; lem = 590 nm) was measured on a Synergy
H1 plate reader (BioTek, Winooski, VT, USA) and data analysis
performed with GraphPad Prism and Microsoft Excel. An F-test
was used to compare growth curves, with p,0.05 considered
statistically significant.
For correlations between fluorescence, luminescence, and cell
number, cells were manually counted by hemocytometer and the
indicated cell numbers plated in 96-well black plates. EGFP
fluorescence (lex = 488 nm; lem = 528 nm) was measured on the
plate reader, then a BrightGlo luciferase assay kit (Promega,
Madison, WI) was used to measure luminescence on the plate
reader according to the manufacturer’s instructions. Pearson’s
correlation coefficients were calculated with Microsoft Excel.
To calculate ng luciferase per mg of cells, a population of Y79-
EGFP-luc cells was counted by hemocytometer, yielding 3.066107
Figure 1. Illustration of the neonatal rat left eye, viewed from
above, showing approximate injection angle and location at
the lateral equator.
doi:10.1371/journal.pone.0099036.g001
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cells with 94% viability. These cells were pelleted into a tared
microfuge tube and found to weigh 1.79 mg per million cells. The
amount of luciferase per million cells was determined in
quadruplicate using a Max Discovery Luciferase ELISA Kit
(BIOO Scientific, Austin, TX, USA), yielding a value of 39.8 ng
luciferase per million cells. The final conversion to ng luciferase
per mg tumor was calculated using the aforementioned tumor cell
weight, yielding 22.2 ng luciferase per mg tumor cells.
Xenograft Generation
All experiments were approved by the Indiana University
School of Medicine Institutional Animal Care and Use Committee
(Protocol 10003) and adhered to all standards set forth in the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, including ensuring all efforts to minimize
suffering. Animals were anesthetized with isoflurane and eutha-
nized by isoflurane overdose followed by decapitation. A pregnant
Sprague-Dawley dam (Harlan, Indianapolis, IN, USA) was housed
individually on a 12-hour light-dark cycle (lights on at 0700) with
access to food and water ad libitum. Within 24 hours of birth,
newborn rat pups (P0) were anesthetized with isoflurane using an
induction box attached to the anesthesia machine (3.0% isoflurane
at an O2 flow of 1.5 L/min; Vetamac, Rossville, IN, USA). After
induction, pups were tattooed on their paws for identification and
then transferred to a heated surgical table to maintain body
temperature at 37uC. Anesthesia was maintained (2.5% isoflurane
at an O2 flow rate of 1.5 L/min) using a modified nosecone for rat
pups.
Under an operating microscope, Vannas scissors were used to
open the eyelid fissure and an additional 2 mm lateral canthotomy
was created for better visualization of the globe. To dilate the
pupil, one drop of tropicamide 1% was placed on the operative
eye. Colibri forceps were used to rotate the eye nasally and a 33G
needle attached to a 5 mL Hamilton syringe was inserted bevel-up
into the intravitreal space at the equator (Fig. 1). Each animal
received a single injection of 103 (n = 9) or 104 (n = 6) Y79-EGFP-
luc cells or a control injection of sterile phosphate buffered saline
(PBS) vehicle (n = 3) into the right eye. Injection of cells or vehicle
Figure 2. Characterization of a Y79 retinoblastoma cell line expressing an EGFP-luciferase fusion protein (Y79-EGFP-luc). (A) Y79-
EGFP-luc cells display identical growth kinetics to the parent cell line (F-test p = 0.49). Y79-EGFP-luc data points shifted right for clarity. (B–D)
Correlations between growth parameters: (B) Luminescence versus cell count; (C) Fluorescence versus cell count; (D) Fluorescence versus
luminescence. Mean 6 SD shown, n = 3 (some error bars are smaller than the data point size).
doi:10.1371/journal.pone.0099036.g002
Table 1. Parameters used for kinetic modeling of luciferin flux, F .
Parameter Value Units Source(s)
Qeff 0.71 N/A Berthold Technologies
Qyld 0.31 Photons/LH2 [27,47]
Eq 6.0261023 LH2/mol [48]
r 1.05 mg/mL [49]
pH 7.0 Log[H+] [26,28]
Km 132580 nM [50–53]
Vmax 1.63610
14 LH2/s.mg [50]
doi:10.1371/journal.pone.0099036.t001
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(1 mL total volume for all injections) was initiated by an assistant
only when the tip of the needle was visualized through the dilated
pupil by the surgeon. The cell suspension or PBS was injected over
a 4–5 second period, and the needle remained in place for 1
minute following injection to minimize reflux when the needle was
removed. Eyes were then thoroughly rinsed with sterile PBS, and
pups were transferred to a homeothermic blanket until they awoke
from anesthesia. Once awake, pups were returned to their mother
in the home cage.
Bioluminescence Imaging
Under isoflurane anesthesia performed as described above,
animals (n = 6, 104 cells injected per eye) were injected subcuta-
neously (s.c.) with VivoGlo D-luciferin potassium salt (Promega),
from a 20 mg/mL stock in PBS. Dosage was 150 mg luciferin per
kg animal weight; animals were weighed immediately prior to each
imaging session. Under maintenance anesthesia, animals were
imaged on the indicated days after injection (P3, P7, P10, P14) on
a NightOwl LB981 (Berthold, Oak Ridge, TN, USA) system.
Animals were imaged on their left sides, 3 at a time until too large
for the chamber, then 2 at a time using full-frame camera height.
Images were gathered over 6 intervals of 5 minutes each, for a
total of 30 minutes’ imaging. In all cases, image import,
visualization, segmentation and quantification were performed
using custom, in-house developed bioluminescence image analysis
software.
Intraocular Imaging
Animals were allowed 2 weeks for natural eye opening before
the intraocular imaging protocol was initiated. Thus, animals
(n = 9, 103 cells injected per eye and n= 3, 0 cells injected per eye)
were imaged 2, 3, and 4 weeks post-injection, with weaning prior
to the 4 week session. On the day of imaging, animals were
transferred to the imaging suite in their home cages and sedated
with dexmedetomidine (0.25–0.5 mg/kg i.p.). Immediately after
sedation, 1% tropicamide was placed on the eye for dilation of the
pupils, followed 1–2 minutes later by topical application of
hypromellose ophthalmic demulcent solution (Gonak; Akorn, Lake
Forest, IL, USA) to help prevent drying of the cornea and cataract
formation. Animals were then placed on a heated platform
attached to a modified microscope stage that allowed movement in
the X, Y, and Z planes as well as rotation around the animal’s
rostral-caudal axis. All in vivo imaging (brightfield, fluorescence,
and OCT) was completed using the Micron III Image Guided
OCT system for rodents (Phoenix Research Labs; Pleasanton, CA,
USA). All animals had brightfield and EGFP fluorescence imaging
completed and images captured using StreamPix software. OCT
image gathering was performed with Micron OCT software. At
the end of each imaging session, sedation was reversed by an
injection of atipamezole (1 mg/kg i.p.).
Figure 3. Modeling of luciferin flux from bioluminescence
imaging (BLI) data reveals slowing of tumor growth over time.
(A) Conventional peak luminescence imaging of xenografts in six
individual animals (each animal is one colored line) shows exponential
tumor growth in the majority of animals. (B) Calculated luciferin flux (F )
modeled (Equations 1–3) from BLI data over the 14-day study. (C)
Pseudo-color parametric images of F for three representative animals at
three timepoints, color-coded as in (A).
doi:10.1371/journal.pone.0099036.g003
Figure 4. Xenograft fluorescence correlates with luminescence.
(A) Ex vivo quantitative fluorescence imaging of six right eyes from six
P14 rats, all of which were injected with Y79-EGFP-luc at P0. (B)
Correlation between fluorescence intensity measured from individual
eyes shown in (A) and peak bioluminescence.
doi:10.1371/journal.pone.0099036.g004
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Figure 5. Characterization of pathology induced by Y79-EGFP-luc retinoblastoma cell xenografts or control injections. Brightfield
(A,D,G,J), green fluorescence (B,E,H,K), and OCT (C,F,I,L) imaging over a 4 week period shown. Tumors were highly vascularized (white arrowheads)
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Ex vivo Analyses
Upon completion of the imaging protocols, the animals were
overdosed with inhaled isoflurane, decapitated, and the eyes
removed for preservation. Each eye was fixed in 4% paraformal-
dehyde at least overnight and then transferred to a 70% ethanol
solution. After removal of anterior chamber and lens, P14 eyes
were imaged for green fluorescence on a Typhoon FLA 9500
molecular imager (GE, Piscataway, NJ, USA) and tumor area
manually delineated and densitized using the Analysis Tools
module of ImageQuant TL software. Whole P29 eyes were
paraffin embedded and 5–7 mm sections were obtained using a
microtome. Sections were then deparaffinized with xylene and
rehydrated in ethanol from 100% to 70%. Sections were stained
using a standard Mayer’s Hematoxylin and Eosin protocol (Sigma,
St. Louis, MO, USA). Briefly, tissue sections were placed in 0.1%
Mayer’s Hematoxylin (filtered prior to use) for 5 minutes and
rinsed in cool running tap H2O for 5 minutes. Sections were then
stained with Eosin (0.5% in 95% ethanol) for 2.5 minutes. Slides
were dipped in tap H2O and then dehydrated in increasing
concentrations of ethanol (70–100%) followed by drying in xylenes
before mounting with Permount (Fisher Scientific, Pittsburgh, PA,
USA). Images were collected using a DM2000 microscope with a
DFC310 FX digital CCD color camera (Leica, Buffalo Grove, IL,
USA).
Results and Discussion
Generation of a Novel EGFP-luciferase Expressing Cell
Line
To allow both BLI and fluorescence imaging of retinoblastoma
cells, we generated a derivative of the Y79 cell line, Y79-EGFP-
luc, expressing a novel lentivirally-encoded EGFP-luciferase fusion
protein; the modified SFFV retrovirus U3 promoter allows for
high levels of EGFP-luciferase fusion protein that are maintained
in vivo. These cells showed identical growth kinetics to the parent
line (Figure 2A), indicating that insertion of the transgene did not
modify the growth characteristics of the cells. Moreover, the
doubling time of these cells of 64 hours (95% CI: 59–70) was
similar to the value of 52 hours reported for Y79 when it was first
and had well-defined edges as seen on brightfield and fluorescence imaging. OCT provided some additional depth resolution not possible with the
other two modalities, although this was limited by shadowing of posterior features. OCT was also able to identify small, distinct satellite tumors
growing independent of the main tumor mass (red arrows). Red lines indicate the OCT planes; L, lens; R, retina.
doi:10.1371/journal.pone.0099036.g005
Figure 6. Histologic analysis of Y79 xenografts reveals intravitreal tumors with morphology closely resembling in vivo OCT
imaging. On OCT imaging in vivo (lower right), this small tumor was seen to be closely apposed to the phakic lens and was noted to have a small
finger-like extension off the main tumor mass. Histologic H&E sections confirmed this same appearance after fixation. L, lens; original magnification,
top= 256, lower left = 1006.
doi:10.1371/journal.pone.0099036.g006
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described 40 years ago [32]. In culture, Y79-EGFP-luc cells
showed excellent linearity of luciferase activity (Figure 2B) and
fluorescence (Figure 2C) with increasing cell number. Importantly,
these two parameters correlated closely (Figure 2D).
Modeling of Luciferin Flux in Orthotopic Xenografts
We injected 10,000 Y79-EGFP-luc cells into the vitreous of P0
rats, and dynamically imaged individual animals with vitreous
xenografts post administration of D-luciferin (LH2). Images were
segmented through time using a semi-automated region of interest
(ROI) tool employing a maximum entropy algorithm [34]. Peak
luminescence (i.e., maximum luminescence signal over time)
demonstrated exponential growth through time (Figure 3A).
We sought to determine if we could obtain more information
than afforded by peak luminescence alone. To this end, we
developed a new mathematical model of average luciferin flux as a
more robust indicator of tumor function; this model was based on
the underlying tumor bioenergetics. Key model assumptions were:
1) Metabolite production by enzymatic cleavage of the LH2 is
observed as photon emission; 2) instantaneous LH2 rates follow
Michaelis-Menten kinetics; and 3) pH, temperature, and quantum
yield during the reaction were all constant. The quantum yield of
photons from the luciferase reaction is less than perfect; for
instance, up to 20% of luciferyl adenylate is involved in a non-
luminescent side reaction yielding H2O2 [35]. In our model, we
incorporated a previously reported quantum yield (Qyld) value for
the luciferase reaction of 0.31 at pH 7.0 [27]. Since to our
knowledge the intracellular pH of retinoblastoma cells has not
been documented, we chose a constant of pH 7.0 based on an
average of published values in other cell types [26,28]. Our model
also incorporated the quantum efficiency (Qeff) of the camera,
0.71 at 530 nm (Berthold, Oak Ridge, TN, USA) (Table 1).
Model estimates of tumor emission volume (Vt) were computed
according to the following:
Vt~
4
3
pr3 ; 0vrƒ0:75 mm
4
3
p(^r{‘)2r ; 0:75vrƒ1:5 mm
2
3
pr^3
 
{ 2
3
p‘3
 
; 1:5vrƒ2:1 mm
8><
>: ð1Þ
Where, r and r^ are the average radius of the ROI and the average
radius of a P14 rat eye, respectively, and ‘ is the computed radius
of a rat lens, 0.625 mm. Based on measurements of enucleated
P14 eyes, we estimated the radius of the eye as 2.1 mm, and used a
literature value of 1.5 mm [36] as the maximum vitreous depth,
i.e., the tumor diameter above which the lens and retina would
limit and mold tumor growth. Given this, 1) small tumors in the
vitreous space (r,0.75 mm) were assumed to be spherical, 2)
tumors with average radii between 0.75 mm and 1.5 mm were
assumed to be elliptically spherical, and 3) tumors with radii
greater than 1.5 mm were assumed to be bowl-shaped following
the contours of the retina and the lens. The tumor size upper
bound was based on the measured radius of the P14 eye (2.1 mm).
To estimate the concentration of LH2 oxidized, photon
luminescent emission was transformed to tumor [LH2] (nM) by
stoichiometric and dimensional analysis using the constants in
Table 1 and Vt from Equation 1. The concentration of metabolite
production with time can then be described by the following
differential equation:
dM
dt
~
(Vmax|C)
(CzKm)
; M(0)~0 ð2Þ
Where M (nmol/s), C (nmol/L), Km (nmol/L), and Vmax (nmol/s)
are the instantaneous rate of LH2 oxidized with time, the
concentration of LH2 oxidized, the Michaelis constant for firefly
luciferase, and the maximum velocity for the LH2/luciferase
reaction, respectively. To estimate F (nmol LH2/s), instantaneous
oxidation rates were integrated with respect to the image
integration period (0 to t, in seconds) and divided by the total
integral period(s) (T) according to:
F~
1
T
ðt
0
M(t)dt ð3Þ
A key distinction of the current model over standard approaches is
that it incorporates the Michaelis-Menten kinetics of luciferase
function. Luminescence directly measures the metabolic oxidation
of the substrate over the image-integration period, and as such,
modeling via Equations 1–3 affords a more direct physiological
interpretation of the supporting biology than traditional approach-
es. This can be seen in Fig. 3, where peak luminescence analysis
shows linear increases in tumor emission with time (Fig. 3A), while
the current F model over this same interval shows a slowing of
turnover by P14 (Fig. 3B, C).
These data suggest that our new model may provide greater
sensitivity to changes in cellular physiology and therefore tumor
health and overall metabolism than peak luminescence alone,
which simply reports information at the maximum emission. This
is particularly true in the bounded environment of the eye, where
tumors can reach a maximal volume and are likely to decrease
metabolism once this maximum is reached.
Ex vivo Intraocular Imaging of Xenografts
To complement modeling of tumor function, we also analyzed
the spatial development of retinoblastoma xenograft growth in our
system. This important aspect of retinoblastoma xenograft biology
has not been previously documented. To determine if intraocular
fluorescence was correlated with tumor size, we quantified
fluorescence of P14 xenografts ex vivo (Figure 4A). As with the
in vitro findings (Figure 2), we confirmed that ex vivo fluorescence
correlated strongly with luminescence (Figure 4B) and both
increased with gross tumor area as measured ex vivo (R2 = 0.98
and 0.95; F-test p,0.001, for fluorescence and luminescence
respectively).
In vivo Intraocular Imaging of Xenografts
In vivo, Y79-EGFP-luc xenografts were characterized by
brightfield (Fig. 5A, D), green fluorescence (Fig. 5B, E), and
OCT (Fig. 5C, F) over a 4 week period. All eyes (even controls)
showed corneal neovascularization, likely due to the trauma of
neonatal eye opening and injection; however, this pathology did
not preclude imaging. Control eyes showed a normal fundus, no
green fluorescence, and clear retinal OCT with no shadowing of
the retina that would be suggestive of xenograft growth.
(Figure 5G–L). All xenografted eyes developed tumors (9/9).
Tumor size varied despite injections of equal cell numbers, which
underscores the importance of BLI as a means to measure baseline
tumor sizes so that tumors can be randomized accurately in future
efficacy studies. On brightfield analysis, tumors were white to off-
white, with prominent blood vessels, and notably dense with well-
defined edges. EGFP signal was helpful in confirming the borders
identified on brightfield analysis.
Multimodality Imaging of Retinoblastoma Orthotopic Xenografts
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e99036
While both of these methods provide detailed information
regarding the width of the tumor, neither provided adequate
information regarding the position within the intravitreal space
nor the height of the tumor. OCT allowed imaging of both normal
retina adjacent to small tumors and the anterior aspect of tumors
abutting the lens. However, these two planes could not be
captured in a single image, so either the retina or the posterior lens
was used as a visual reference point for imaging. OCT was
beneficial in identifying the anterior face of the tumor and its
proximity to the lens, as well as ‘‘satellite’’ lesions separate from the
main tumor mass (Fig. 5C). In addition, large, vitreous-filling
tumors that were hard to demarcate on brightfield imaging
(Fig. 5D) were readily identified by OCT (Fig. 5F). OCT
confirmed the presence of blood vessels within the tumor mass
(Fig. 5F) as noted by brightfield (Fig. 5D) and fluorescence (Fig. 5E)
imaging. Although little information on the posterior aspect of
xenografts could be gleaned by OCT due to shadowing by the
anterior aspect of the tumors, the ability to quickly confirm the
presence and location of a xenograft in an animal eye is important.
This methodology will allow the rapid profiling of multiple
retinoblastoma cell lines to obtain a panel of orthotopic xenografts
that can be used for therapeutic trials. Such a panel might better
represent the variable genetic backgrounds and phenotypes of
human tumors [2,3].
Histologic analysis recapitulated morphology seen by OCT and
confirmed preferential localization of small tumors to the
intravitreal space above the optic nerve head (Fig. 6). It appeared
that tumors filled the intravitreal space until coming into contact
with the phakic lens, consistent with the assumptions of intravitreal
tumor shape incorporated into our BLI model (Equation 1).
During the one minute post-injection period, while the needle
remained visualized in the vitreous space prior to withdrawal,
injectate was seen to begin spreading. These cells are likely
dispersed through the vitreous in the post-operative recovery
period. We believe our later localization data indicate for the first
time that viable Y79 retinoblastoma orthotopic xenografts likely
form near the optic nerve head, where they can obtain their
nutrient and blood supply from the neonatal hyaloid artery prior
to its natural regression. As in other invasive tumors [37], we
hypothesize that pro-angiogenic factors are released from the
retinoblastoma xenografts, resulting in large, highly vascularized
tumors. This assertion is supported by evidence that retinoblas-
toma subcutaneous xenografts depend on VEGF signaling for
growth [38].
Conclusions
There is a long history of xenografting retinoblastoma cell lines
into mice, rats, and rabbits [39]; even recently zebrafish [40]. Cells
and tumor material have been delivered subcutaneously [41],
intravenously [13], into the anterior chamber [42], and by
intravitreal, subretinal, and subconjunctival routes [13]. Tradi-
tionally, successful orthotopic xenografts were confirmed by
fundus photography, signs such as progressive proptosis seen on
examination as tumors grow, and postmortem histopathology.
Recently, prior to xenografting into rodents, retinoblastoma cell
lines have been genetically manipulated to express EGFP,
luciferase, or a dual construct of both (EGFP-luc) as methods to
follow tumor growth [12–14,16,17,43]. More rapid and quanti-
tative ascertainment of xenograft success and growth would be
advantageous.
For the first time, we have shown that a Y79-EGFP-luc cell line
creates viable xenografts in the newborn rat model. Further, we
have shown that the ability to monitor xenograft growth spatially
in the eye as well as model tumor function offers considerable
utility for future therapeutic trials. Subtle readouts of compound
activity, such as diffusion, thinning, or movement of the tumor
mass, loss of xenograft core fluorescence, and decreased F are
likely to provide sensitive measures of the efficacy of experimental
agents, even when gross effects on tumor volume or peak
luminescence are modest. In addition, our imaging methodologies
complement what is possible in transgenic retinoblastoma models,
one of which has previously been examined using OCT [44–46].
Transgenic models have the advantage of intraretinal tumors more
readily documented by OCT without shadowing, but lack the
human cell origin and ability to quantitatively follow tumor
growth by BLI as in the current system.
Therefore, we believe the current model greatly enhances the
traditional approaches, and will provide additional key informa-
tion necessary for future studies of novel therapeutics in
retinoblastoma. Moreover, this system allows us to rapidly expand
preclinical xenograft studies to additional retinoblastoma cell lines
and move beyond the aggressive Y79 cell line commonly used.
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